Prof. Tom Vanden Berghe obtained a Master and a PhD in Science (Biotechnology) in 1999 and 2005, respectively. He was a postdoc at the VIB-UGent Center for Inflammation Research and became Assistant professor at UAntwerp and Guest professor at Gent University in 2018.
Prof. Tom Vanden Berghe is running two labs: Pathophysiology lab @UAntwerp and Ferroptosis and Inflammation Research lab @VIB-UGent. His mission is to perform applied research in the context of cell death/ferroptosis, inflammation and disease. The Vanden Berghe lab studies the mechanisms, diagnostics and intervention strategies in critical illness, brain injuries, chronic kidney disease, vascular calcification and bone metabolism. Along the in vivo validation of patented lead ferroptosis inhibitors, the Vanden Berghe lab also explores ferroptosis as novel anti-cancer therapy to eradicate therapy-resistant cancers. He has setup a multi-faceted ferroptosis platform covering novel lead ferroptosis inhibitors & genes, ferroptosis diagnostics, as well as ferroptosis nanomedicine anti-cancer therapeutics.
Professor @ UAntwerp
Guest Professor @ UGent
Research coordinator
10% ZAP
Vascular calcification
Postdoctoral fellow
10% ZAP
Kidney disease
Ferroptosis
Anti-cancer therapeutics
Mechanisms of vascular calcification
Ferroptosis
Multiple sclerosis
Ferroptosis
Epigenetics
Nephrectomy induced repair
Ferroptosis
Chronic interstitial nephritis
Ferroptosis
Nonalcoholic fatty liver disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Chronic kidney disease
Ferroptosis
Ischemia/reperfusion injury
Ferroptosis
Mechanism lipid peroxidation
Endothelial cells
Vascular calcification
Nephrectomy
Regeneration
Precision medicine 2.0 diagnostics
Nanopore episequencing cfDNA
Critical illness
Administration
Biochemical analysis
Experimental surgery
Bone histomorphometry
Biochemical analysis
Biomedical Laboratory
Spectrometric Analyses
Experimental surgery
Animal follow-up
Bone histomorphometry
Toxin induced nephropathy
Arterial stiffness in vascular calcification
Metformin
Chronic kidney disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Immunogenicity
Ferroptosis
Multi organ failure
Experimental surgery
Mouse manager
Standard lab analysis
Postdoctoral fellow
Bone histomorphometry
| Title | Cited by |
|
2023
Ferroptosis and pyroptosis signatures in critical COVID-19 patients
Cell Death & Differentiation, 1-12, 2023
|
0
|
|
2023
Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression
Cell Death & Differentiation, 1-12, 2023
|
0
|
|
2023
Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques
Angiogenesis, 1-18, 2023
|
0
|
|
2023
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Cell Death & Differentiation, 1-58, 2023
|
15
|
|
2023
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD
European Respiratory Journal 61 (4), 2023
|
5
|
|
2023
Molecular mechanisms of nemorosone-induced ferroptosis in cancer cells
Cells 12 (5), 735, 2023
|
2
|
|
2023
Caspase inhibition modulates monocyte-derived macrophage polarization in damaged tissues
International Journal of Molecular Sciences 24 (4), 4151, 2023
|
1
|
|
2023
Zonated quantification of immunohistochemistry in normal and steatotic livers
Virchows Archiv, 1-11, 2023
|
1
|
|
2022
Zonated quantification of immunohistochemistry in steatotic livers
Journal of Hepatology 77, S709, 2022
|
0
|
|
2022
Correction to: Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen–glucose Deprivation
Neurotherapeutics 19 (4), 1433, 2022
|
0
|
|
2022
Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
Nature communications 13 (1), 3676, 2022
|
69
|
|
2022
Novel iron oxide nanoparticles induce ferroptosis in a panel of cancer cell lines
Molecules 27 (13), 3970, 2022
|
20
|
|
2022
Inhibiting RIPK1 kinase activity is protective in experimental models of COPD
ERJ Open Research 8 (suppl 8), 2022
|
1
|
|
2022
Luminescent human iPSC-derived neurospheroids enable modeling of neurotoxicity after oxygen–glucose deprivation
Neurotherapeutics 19 (2), 550-569, 2022
|
7
|
|
2022
Targeting ferroptosis protects against experimental (multi) organ dysfunction and death
Nature communications 13 (1), 1046, 2022
|
38
|
|
2022
Executioner caspases 3 and 7 are dispensable for intestinal epithelium turnover and homeostasis at steady state
Proceedings of the National Academy of Sciences 119 (6), e2024508119, 2022
|
8
|
|
2021
Necroptosis signaling promotes inflammation, airway remodeling, and emphysema in chronic obstructive pulmonary disease
American journal of respiratory and critical care medicine 204 (6), 667-681, 2021
|
70
|
|
2021
Ferroptosis: biological rust of lipid membranes
Antioxidants & Redox Signaling 35 (6), 487-509, 2021
|
35
|
|
2021
Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL
Cell death & disease 12 (5), 1-10, 2021
|
14
|
|
2021
3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl) ethyl) benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating eg stroke
US Patent App. 16/967,871, 2021
|
1
|
| Number | Name | Date |
| US9862678, WO2016075330, EP3218357 | 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death | 2014-11-14 |
| WO2019154795, EP3749645, CN112105601, US20210094909, 201980012162.8 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | 2018-02-07 |
| WO2015110346, US9919048 | Targeting of interleukin-1 and -18 signaling in treatment of septic shock | 2014-01-21 |
| EP22196811 | New Ferroptosis Inhibitors | 2022-09-21 |
